aplb glutathione niacinamide facial cream inci ingredients (Explained) APLB cream has antioxidant properties APLB Glutathione Niacinamide Facial Cream

14,15 Lapeque et al (2014) provide a practical review on BP ultrasound

The multiple sclerosis model using cuprizone-induced demyelination demonstrated reduced motor disability and preserved myelin with peptide treatment

Free radicals are unstable molecules produced naturally in the body as a by-product of metabolism, stress, UV exposure, pollution, or poor lifestyle habits

As CEO Todd Zavodnick put it: A lot of patients are being undertreated and we believe this market is massive. #Biotech #AllergyInnovation #Immunology #LifeSciences #FundingNews To view or add a comment, sign in Improvement of the therapeutic management of allergic patients in Europe An expert think tank's position paper on allergen immunotherapy To view or add a comment, sign in Yuhan Corporation's novel allergy drug lesigercept gains IND approval from MFDS for Phase 2 clinical trials - 12-week treatment for 150 patients with chronic spontaneous urticaria - Study to confirm safety, efficacy, and clinical benefits in an expanded patient cohort in Asia and Europe Yuhan Corporation announced on October 15 that it received approval from the Ministry of Food and Drug Safety (MFDS) on October 14 for its Phase 2 clinical trial plan (IND) for lesigercept (development code YH35324). Lesigercept is a novel anti-Immunoglobulin E (IgE) Fc fusion protein drug designed to alleviate allergic symptoms through a dual mechanism of action, by binding to and eliminating both free IgE and IgE receptor alpha (FcRI) autoantibodies present in the bloodstream